About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–Clear

2 catalysts

Regulatory and ClinicalSPA AgreementSep 24, 2026 · 6:06am ET

ATYRaTYR PHARMA INC

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Company expects to initiate study-related activities in Q4 2026.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+90.1%

RVOL

4.7x

Max high

$0.73

Fuel

12m

Regulatory and ClinicalSPA AgreementSep 24, 2026 · 6:06am ET

ATYRaTYR PHARMA INC+90.1%

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

RVOL

4.7x

Max high

$0.73

Fuel

12m

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

FDA agrees to Phase 3 design including UMSARS Part I as primary endpoint.

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD+57.2%

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

RVOL

8.7x

Max high

$6.78

Fuel

1m